The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-24. Anything still debated is marked as such rather than presented as settled.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
==== 1900–1999 ==== Local Government (Scotland) Act 1975 (Local Authority Borrowing Limit) Order 1993 (S.I. 1993/1900) Nurses, Midwives and Health Visitors (Entry to Examinations and Training Requirements) Amendment Rules Approval Order 1993 (S.I. 1993/1901) Trade Union Reform and Employment Rights Act 1993 (Commencement No. 1 and Transitional Provisions) Order 1993 (S.I. 1993/1908) Trade Union Ballots and Elections (Independent Scrutineer Qualifications) Order 1993 (S.I. 1993/1909) Teddington Memorial Hospital National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/1932) Money Laundering Regulations 1993 (S.I. 1993/1933) Public Telecommunication System Designation (Scottish Hydro-Electric plc) Order 1993 (S.I. 1993/1934) Public Telecommunication System Designation (Energis Communications Limited) Order 1993 (S.I. 1993/1935) Education (Assisted Places) (Amendment) Regulations 1993 (S.I. 1993/1936) Education (Assisted Places) (Incidental Expenses) (Amendment) Regulations 1993 (S.I. 1993/1937) Education (Grants) (Music and Ballet Schools) (Amendment) Regulations 1993 (S.I. 1993/1938) Social Security (Disability Living Allowance) (Amendment) Regulations 1993 (S.I. 1993/1939) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No.4 and No.7) Orders 1993 Revocation Order 1993 (S.I. 1993/1940) Value Added Tax (General) (Amendment) (No. 6) Regulations 1993 (S.I. 1993/1941) Road Vehicles (Construction and Use) (Amendment) (No. 1) Regulations 1993 (S.I. 1993/1946) Tobacco Products Labelling (Safety) Amendment Regulations 1993 (S.I.
=== Chemical flocculant === Potassium alum has been used since remote antiquity for purification of turbid liquids. It is still widely used in the purification of water for drinking and industrial processes water, treatment of effluents and post-storm treatment of lakes to precipitate contaminants. Between 30 and 40 ppm of alum for household wastewater, often more for industrial wastewater, is added to the water so that the negatively charged colloidal particles clump together into "flocs", which then float to the top of the liquid, settle to the bottom of the liquid, or can be more easily filtered from the liquid, prior to further filtration and disinfection of the water. Like other similar salts, it works by neutralizing the electrical double layer surrounding very fine suspended particles, allowing them to join into flocs. The same principle is exploited when using alum to increase the viscosity of a ceramic glaze suspension; this makes the glaze more readily adherent and slows its rate of sedimentation.
Some molecules have simple spectra which are easy to identify, whilst others (even some small molecules) have extremely complex spectra with flux spread among many different lines, making them far harder to detect. Interactions between the atomic nuclei and the electrons sometimes cause further hyperfine structure of the spectral lines. If the molecule exists in multiple isotopologues (versions containing different atomic isotopes), the spectrum is further complicated by isotope shifts. Detection of a new interstellar or circumstellar molecule requires identifying a suitable astronomical object where it is likely to be present, then observing it with a telescope equipped with a spectrograph working at the required wavelength, spectral resolution and sensitivity. The first molecule detected in the interstellar medium was the methylidyne radical (CH•) in 1937, through its strong electronic transition at 4300 angstroms (in the optical). Advances in astronomical instrumentation have led to increasing numbers of new detections. From the 1950s onwards, radio astronomy began to dominate new detections, with sub-mm astronomy also becoming important from the 1990s. The inventory of detected molecules is highly biased towards certain types which are easier to detect. For example, radio astronomy is most sensitive to small linear molecules with a high molecular dipole.
The design of the flame ionization detector varies from manufacturer to manufacturer, but the principles are the same. Most commonly, the FID is attached to a gas chromatography system. The eluent exits the gas chromatography column (A) and enters the FID detector’s oven (B). The oven is needed to make sure that as soon as the eluent exits the column, it does not come out of the gaseous phase and deposit on the interface between the column and FID. This deposition would result in loss of eluent and errors in detection. As the eluent travels up the FID, it is first mixed with the hydrogen fuel (C) and then with the oxidant (D). The eluent/fuel/oxidant mixture continues to travel up to the nozzle head where a positive bias voltage exists. This positive bias helps to repel the oxidized carbon ions created by the flame (E) pyrolyzing the eluent. The ions (F) are repelled up toward the collector plates (G) which are connected to a very sensitive ammeter, which detects the ions hitting the plates, then feeds that signal to an amplifier, integrator, and display system(H). The products of the flame are finally vented out of the detector through the exhaust port (J).
This demonstrates the Druze adherence to Christian teachings on marriage and the value of marital mutual relationships. Overall, the Druze community's approach to marriage closely resembles that of Christians.
Sources: en.wikipedia.org
TSAVLQ-SGFRK-NH2 and SGVTFQ-GKFKK are the two peptides corresponding to the two self-cleavage sites of the SARS 3C-like proteinase The protease is important in the processing of the coronavirus replicase polyprotein (P0C6U8). It is the main protease in coronaviruses and corresponds to nonstructural protein 5 (nsp5). It cleaves the coronavirus polyprotein at 11 conserved sites. The 3CL protease has a cysteine-histidine catalytic dyad at its active site. The sulfur of the cysteine acts as a nucleophile and the imidazole ring of the histidine as a general base.
In June 1884, British imperial interests were ignited in the discovery by Jan Gerrit Bantjes of what would prove to be the world's largest deposit of gold ore at an outcrop on a ridge 69 km (43 mi) south of the Boer capital at Pretoria. The ridge was known locally as the "Witwatersrand" (white water ridge, a watershed). A gold rush to the Transvaal brought thousands of British and other prospectors from around the globe and over the border from the Cape Colony, which had been under British control since 1806.
CH2=CHCH3 + 1/2 O2 + CH3CO2H → CH2=CHCH2O2CCH3 + H2O Hydrolysis of this acetate gives allyl alcohol. In alternative fashion, propylene can be oxidized to acrolein, which upon hydrogenation gives the alcohol. In principle, allyl alcohol can be obtained by dehydrogenation of propan-1-ol.
== Bibliography == McNeill, A; Brose, LS; Calder, R; Bauld, L; Robson, D (February 2018). "Evidence review of e-cigarettes and heated tobacco products 2018" (PDF). UK: Public Health England. pp. 1–243. Stratton, Kathleen; Kwan, Leslie Y.; Eaton, David L. (January 2018). Stratton, Kathleen; Kwan, Leslie Y.; Eaton, David L. (eds.). Public Health Consequences of E-Cigarettes (PDF). National Academies of Sciences, Engineering, and Medicine (National Academies Press). pp. 1–774. Bibcode:2018nap..book24952N. doi:10.17226/24952. ISBN 978-0-309-46834-3. PMID 29894118. McNeill, A; Brose, LS; Calder, R; Hitchman, SC; Hajek, P; McRobbie, H (August 2015). "E-cigarettes: an evidence update" (PDF). UK: Public Health England. pp. 1–113. "Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS)" (PDF). World Health Organization WHO. August 2016. pp. 1–11. Wilder, Natalie; Daley, Claire; Sugarman, Jane; Partridge, James (April 2016). "Nicotine without smoke: Tobacco harm reduction". UK: Royal College of Physicians. pp. 1–191. "State Health Officer's Report on E-Cigarettes: A Community Health Threat" (PDF). California Tobacco Control Program. California Department of Public Health. January 2015. pp. 1–21. This article incorporates text from this source, which is in the public domain.
Sources: en.wikipedia.org
The xanthoproteic reaction (xanthoprotic test) is a method that can be used to detect a presence of protein soluble in a solution, using concentrated nitric acid. The test gives a positive result in amino acids carrying aromatic groups, especially in the presence of tyrosine. If the test is positive the proof is neutralized with an alkali, turning dark yellow. The yellow colour is due to xanthoproteic acid which is formed due to nitration of certain amino acids, most common examples being tyrosine and tryptophan. This chemical reaction is a qualitative test, determining the presence or absence of proteins.
Patulin is an organic compound classified as a polyketide. It is named after the fungus from which it was isolated, Penicillium patulum. It is a white powder soluble in acidic water and in organic solvents. It is a lactone that is heat-stable, so it is not destroyed by pasteurization or thermal denaturation. However, stability following fermentation is lessened. It is a mycotoxin produced by a variety of molds, in particular, Aspergillus and Penicillium and Byssochlamys. Most commonly found in rotting apples, the amount of patulin in apple products is generally viewed as a measure of the quality of the apples used in production. In addition, patulin has been found in other foods such as grains, fruits, and vegetables. Its presence is highly regulated.
Ariel Steinberg (born 26 August 1992 in Mildura, Victoria, Australia) is an Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). He made his senior debut against West Coast in round 21 of the 2014 season.
The three major units of aquasomes are fabricated together according to self-assembly, a thermodynamically driven process that organizes subunits of a system in a manner that results in the lowest Gibbs free energy available, known as ΔG. Self-assembly as a mixing process offers high accuracy and control over sizes on the nanometer scale, which is especially relevant for aquasomes, which exist on this size scale. The three layers of aquasomes can be synthesized differently using a variety of techniques depending on the intended functions or desired therapeutic effects. The general scheme of aquasome fabrication involves a sequential synthesis of a nanocrystalline core, followed by a polyhydroxy coating, and finished with integration of bioactive molecules. Throughout this process, several intermittent steps are included that involve selective filtering and purification to remove byproducts while isolating the desired products for further processing.
MRI offers the greatest image resolution and can provide diagnostic information on presence of soft tissue infection or bone infection. Like ultrasound, MRI does not expose patients to radiation, however it is the slowest and most difficult to implement of all of these imaging methods. Laboratory studies: Serum prealbumin levels may be useful in evaluating nutrition status in patients with chronic wounds or at risk for developing chronic wounds. Elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) can confirm presence of an infection but alone are not diagnostic. Routine bloodwork such as a basic metabolic panel (BMP) or complete blood count (CBC) are not typically required but may be useful in select circumstances. Ankle-brachial index/toe-brachial index (ABI/TBI): These tests can be used to assess blood supply to the lower extremities and their results may affect management of lower extremity wounds such as venous/arterial ulcers, diabetic foot ulcers, or pressure ulcers.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.